Skip to main content
Equibles
CGTX logo

CGTX · Cognition Therapeutics Inc · Metrics

Track CGTX — free

Use CGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.76 +0.00 (+0.54%) Q4 2024 earnings call transcript
Rebalance outlook locked
Market Cap
$72.19M
Shares
95.09M
Volume · Oct 28 74.15K Avg daily vol (3M) 516.43K

CGTX metrics

56 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.76
Market cap
$72.19M

Price action

20 metrics
Price change (1W)
+3.4%
Price change (30D)
-19.1%
Price change (3M)
-17.8%
Price change (6M)
-40.7%
Price change (YTD)
-43.8%
Price change (1Y)
-54.8%
Trailing year
Price change (5Y)
-93.7%
52-week high
$1.80
52-week low
$0.60
Change from 52-week high
-57.8%
Change from 52-week low
+27.6%
Annualized volatility
97.0%
Annualized volatility (3M)
55.5%
Beta
2.8
RSI (14D)
39.0
Price vs SMA 50
-18.2%
Price vs SMA 200
-29.5%
Avg volume (3M)
516,434
Relative volume
0.6
Average dollar volume
$481,753

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
95.09M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.2
reciprocal yield 45.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-23.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-26

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$36.60M
Net income (TTM)
−$16.77M
Trailing 12 months
Diluted EPS (TTM)
$-0.16
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.39

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+42.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-50.8%
Return on assets
-43.1%
Debt / equity
—
Current ratio
7.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$34.01M
Latest balance sheet
Cash & equivalents
$34.01M
Total assets
$38.90M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$17.68M
Capital expenditures (TTM)
—
R&D (TTM)
$26.14M
SG&A (TTM)
—
Stock compensation (TTM)
$1.53M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
66
13F filer change QoQ
-9
Institutional ownership
23.8%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
13.5%
Private-fund adviser ownership
12.9%
Active holders' share change QoQ
+2.3%
Holder tenure
6.2
Price vs estimated holder cost
-20.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.7%

Short interest

3 metrics
Short interest
7.4%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1455365 CUSIP 19243B102 13F (30d) 14 filings 14 filers Visit website Investor relations